Time to separate MOG-Ab-associated disease from AQP4-Ab-positive neuromyelitis optica spectrum disorder

Time to separate MOG-Ab-associated disease from AQP4-Ab-positive neuromyelitis optica spectrum disorder

Bibliographic Details
Main Authors:	Hacohen, Y, Palace, J
Format:	Journal article
Language:	English
Published:	American Academy of Neurology 2018

Similar Items

Characterizing mortality in patients with AQP4‐Ab + neuromyelitis optica spectrum disorder
by: Francis, A, et al.
Published: (2024)

The influence of smoking on the pattern of disability and relapse risk in AQP4-positive Neuromyelitis Optica Spectrum Disorder, MOG-Ab Disease and Multiple Sclerosis
by: Messina, S, et al.
Published: (2021)

Anti-MOG Antibodies in Japanese Patients with Neuromyelitis Optica Spectrum Disorders
by: Sato, D, et al.
Published: (2014)

Frequency of Aqp4-Ab in patients with neuromyelitis optica (Devic's syndrome) is higher than predicted by NMO-IgG testing
by: Jarius, S, et al.
Published: (2007)

Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder.
by: Pittock, S, et al.
Published: (2019)

The role of imaging in diagnosing neuromyelitis optica spectrum disorder
by: Matthews, L, et al.
Published: (2014)

The role of imaging in diagnosing neuromyelitis optica spectrum disorder
by: Matthews, L, et al.
Published: (2013)

Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders.
by: Sato, D, et al.
Published: (2014)

Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders.
by: Kezuka, T, et al.
Published: (2014)

Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset.
by: Collongues, N, et al.
Published: (2013)

Influence of pregnancy on neuromyelitis optica spectrum disorder.
by: Kim, W, et al.
Published: (2012)

Racial differences in neuromyelitis optica spectrum disorder
by: Kim, S, et al.
Published: (2018)

Pregnancy outcomes in aquaporin-4-positive neuromyelitis optica spectrum disorder.
by: Nour, M, et al.
Published: (2015)

The impact of neuromyelitis optica spectrum disorder on pregnancy outcome
by: Nour, M, et al.
Published: (2014)

Diagnosis of neuromyelitis optica (NMO) spectrum disorders: is MRI obsolete?
by: Downer, J, et al.
Published: (2012)

Diagnosis of neuromyelitis optica (NMO) spectrum disorders: Is MRI obsolete?
by: Downer, J, et al.
Published: (2012)

THE ASSOCIATION OF TWO RARE NEUROLOGICAL DISEASES: A MULTICENTRE STUDY OF 16 PATIENTS WITH ACHR ANTIBODY MYASTHENIA GRAVIS AND AQP4 ANTIBODY NEUROMYELITIS OPTICA SPECTRUM DISORDER
by: Leite, M, et al.
Published: (2012)

The evolving clinical spectrum of neuromyelitis optica
by: Viegas, S, et al.
Published: (2008)

Factors associated with fatigue in CNS inflammatory diseases with AQP4 and MOG antibodies
by: Yeo, T, et al.
Published: (2020)

Low levels of vitamin D in neuromyelitis optica spectrum disorder: association with disease disability
by: Min, J, et al.
Published: (2014)

NEUROMYELITIS OPTICA SPECTRUM DISORDER AND CMV RETINITIS: A CASE REPORT
by: George, J, et al.
Published: (2012)

CAN MRI BE USED AS A DIAGNOSTIC TOOL IN NEUROMYELITIS OPTICA SPECTRUM DISORDER?
by: Matthews, L, et al.
Published: (2012)

Anti-aquaporin 4 antibody-positivity of Korean patients with neuromyelitis optica spectrum disorders
by: Min, J, et al.
Published: (2010)

The borderland of neuromyelitis optica.
by: Matthews, L, et al.
Published: (2009)

Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies
by: Kitley, J, et al.
Published: (2013)

Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies.
by: Kitley, J, et al.
Published: (2013)

Cell-based assay for anti-AQP4 antibody in Korean patients with neuromyelitis optica
by: Kim, B, et al.
Published: (2010)

Alternative antigen targets in aquaporin-4 antibodynegative neuromyelitis optica spectrum disorders
by: Kitley, J, et al.
Published: (2013)

NEUROMYELITIS OPTICA SPECTRUM AND RELATIONSHIP WITH AQUAPORIN-4 ANTIBODY DISEASE: THE OXFORD COHORT
by: Leite, M, et al.
Published: (2009)

Distinguishing the brain MRI features of MS, AQP4-and MOG-antibody disease.
by: Jurynczyk, M, et al.
Published: (2016)

Risk factors for immunosuppression-associated infections in aquaporin-4 antibody mediated neuromyelitis optica spectrum disorders
by: Cheng, F, et al.
Published: (2014)

Features of neuromyelitis optica spectrum disorders and aquaporin-4 with myelin-oligodendrocyte glycoprotein antibodies-reply.
by: Kitley, J, et al.
Published: (2014)

Characterization of the spectrum of Korean inflammatory demyelinating diseases according to the diagnostic criteria and AQP4-Ab status.
by: Kim, S, et al.
Published: (2014)

Use of mitoxantrone in neuromyelitis optica.
by: Kitley, J, et al.
Published: (2011)

Pain in neuromyelitis optica spectrum disease: a cross-sectional study in an English cohort
by: Leonard, H, et al.
Published: (2012)

Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan
by: Kitley, J, et al.
Published: (2012)

Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan.
by: Kitley, J, et al.
Published: (2012)

TREATMENT OF NEUROMYELITIS OPTICA WITH AZATHIOPRINE
by: Elsone, L, et al.
Published: (2012)

Myasthenia gravis and neuromyelitis optica spectrum disorder: a multicenter study of 16 patients.
by: Leite, M, et al.
Published: (2012)

Bortezomib for neuromyelitis optica spectrum disorder: a new therapeutic option for the more severe forms? Does bortezomib inform our understanding of the immunology underlying neuromyelitis optica spectrum disorders?
by: Taylor, J, et al.
Published: (2017)